María Varela, MD, PhD, discusses the findings from a real-life analysis to confirm the benefit of regorafenib as treatment of patients with hepatocellular carcinoma who have progressed on prior sorafenib. Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
María Varela, MD, PhD, a pathologist in the Liver Unit at the Hospital Universitario Central de Asturias, discusses the findings from a real-life analysis to confirm the benefit of regorafenib (Stivarga) as treatment of patients with hepatocellular carcinoma (HCC) who have progressed on prior sorafenib (Nexavar). Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
If patients with HCC moved to regorafenib at the time of radiographic progression, they obtained better survival with regorafenib than if they stayed on sorafenib, Varela says. The survival for second-line regorafenib was estimated at 28 months versus 8 months with sorafenib, according to Varela.
There is some bias inthis real-life observational cohort
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More